{
    "clinical_study": {
        "@rank": "104105", 
        "arm_group": [
            {
                "arm_group_label": "Period 1: 960 mg tafamidis (Vyndaqel)", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Period 2: 400 mg moxifloxacin", 
                "arm_group_type": "Experimental", 
                "description": "400 mg moxifloxacin"
            }, 
            {
                "arm_group_label": "Period 3: Placebo", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to investigate the effects of tafamidis on the intervals of the\n      electrocardiogram, specifically the rate corrected QT interval (QTc) in healthy volunteers."
        }, 
        "brief_title": "A Study To Determine Any Effect Of Tafamidis On Electrocardiographic Intervals, Specifically The Rate Corrected QT Interval (QTc)", 
        "completion_date": {
            "#text": "April 2013", 
            "@type": "Actual"
        }, 
        "condition": "TTR Cardiomyopathy", 
        "condition_browse": {
            "mesh_term": "Cardiomyopathies"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy, nonsmoking, male and/or female subjects of non-childbearing potential.\n\n          -  Body Mass Index (BMI) of 17.5 to 30.5 kg/m2.\n\n          -  Total body weight >50 kg (110 lbs).\n\n        Exclusion Criteria:\n\n          -  Evidence or history of clinically significant hematological, renal, endocrine,\n             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or\n             allergic disease.\n\n          -  An ALT or AST measurement >2 times the ULN.\n\n          -  12-lead ECG demonstrating QTc >450 msec or a QRS interval >120 msec at Screening.\n\n          -  Subjects at increased risk if dosed with moxifloxacin, according to the product label\n             for moxifloxacin.\n\n          -  History of risk factors of QT prolongation or torsades de pointes, congenital\n             deafness and family history of sudden death."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "42", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01775761", 
            "org_study_id": "B3461031"
        }, 
        "intervention": [
            {
                "arm_group_label": "Period 1: 960 mg tafamidis (Vyndaqel)", 
                "description": "A comparison of less than or equal to 960 mg tafamidis, 400 mg moxifloxacin and placebo on the rate corrected QT interval.", 
                "intervention_name": "Period 1", 
                "intervention_type": "Drug", 
                "other_name": "tafamidis (Vyndaqel)"
            }, 
            {
                "arm_group_label": "Period 2: 400 mg moxifloxacin", 
                "description": "A comparison of less than or equal to 960 mg tafamidis, 400 mg moxifloxacin and placebo on the rate corrected QT interval.", 
                "intervention_name": "Period 2", 
                "intervention_type": "Drug", 
                "other_name": "moxifloxacin"
            }, 
            {
                "arm_group_label": "Period 3: Placebo", 
                "description": "A comparison of less than or equal to 960 mg tafamidis, 400 mg moxifloxacin and placebo on the rate corrected QT interval.", 
                "intervention_name": "Period 3", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Moxifloxacin", 
                "Norgestimate, ethinyl estradiol drug combination"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "Thorough QTc evaluation of tafamidis compared to the effects of moxifloxacin and placebo in healthy volunteers.", 
        "lastchanged_date": "May 20, 2013", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B3461031&StudyName=A%20Study%20To%20Determine%20Any%20Effect%20Of%20Tafamidis%20On%20Electrocardiographic%20Intervals%2C%20Specifically%20The%20Rate%20Corrected%20QT%20Interval%20%28QTc%29"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "New Haven", 
                        "country": "United States", 
                        "state": "Connecticut", 
                        "zip": "06511"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bruxelles", 
                        "country": "Belgium", 
                        "zip": "B-1070"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Singapore", 
                        "country": "Singapore", 
                        "zip": "188770"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Belgium", 
                "Singapore"
            ]
        }, 
        "number_of_arms": "3", 
        "official_title": "A Randomized, Placebo- And Positive-Controlled Cross-Over Study To Evaluate The Effect Of Tafamidis On The QTC Interval In Healthy Volunteers", 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "April 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "QTc interval using Fridericia's correction method (QTcF) of tafamidis and placebo (baseline-adjusted) at each post-dose time", 
            "safety_issue": "Yes", 
            "time_frame": "SCRN, -1, -0.5, 0, 1, 1.5, 2, 3, 4, 6, 12, 24 hrs"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01775761"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "QTcF of moxifloxacin and placebo at historical moxifloxacin median Tmax of 3 hours.", 
                "safety_issue": "Yes", 
                "time_frame": "Scrn, -1, -0.5, 0, 1, .5, 2, 3, 4, 6, 8, 12, 24 hrs"
            }, 
            {
                "measure": "Tmax", 
                "safety_issue": "No", 
                "time_frame": "0, 1, .5, 2, 3, 4, 6, 8, 12, 24 hrs"
            }, 
            {
                "measure": "Cmax", 
                "safety_issue": "No", 
                "time_frame": "0, 1, .5, 2, 3, 4, 6, 8, 12, 24 hrs"
            }, 
            {
                "measure": "AUC0-24", 
                "safety_issue": "No", 
                "time_frame": "0, 1, .5, 2, 3, 4, 6, 8, 12, 24 hrs"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}